Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2023 | ATOMIC: treating mesothelioma with an arginine-degrading enzyme and combination chemotherapy

Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, comments on the objectives and results of the ATOMIC (NCT02709512) clinical trial. This Phase II/III trial took advantage of the noticed vulnerability that non-epithelioid mesotheliomas have to arginine deprivation, and therefore studied the significance of using ADI-PEG 20, an arginine-degrading enzyme, with combination chemotherapy. The primary endpoints of PFS and OS were met. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultancy fees for RSOncology and Speaker bureau for BMS.